Treatment Clinical Trials for Non-Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for non-small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 437

  • M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

    The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
    Location: 8 locations

  • A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

    The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab.
    Location: 14 locations

  • A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495 / KEYNOTE-495)

    This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
    Location: 13 locations

  • Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant / Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671 / KEYNOTE-671)

    This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant phase] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by blinded central pathologist or by imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) assessed by blinded independent central review (BICR); and 2) overall survival (OS).
    Location: 8 locations

  • A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma

    Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin / pemetrexed. RGX-104 activates LXR, resulting in depletion of both myeloid-derived suppressor cells (MDSCs) as well as tumor blood vessels. MDSCs block the ability of T-cells and other cells of the immune system from attacking tumors. During the dose escalation stage, multiple doses and schedules of orally administered RGX-104 with or without nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin / pemetrexed (single agent or combination therapy) will be evaluated in patients with advanced solid tumors and lymphoma (i.e., locally advanced and unresectable, or metastatic) who have had progressive disease (PD) on available standard systemic therapies or for which there are no standard systemic therapies of relevant impact. Dose escalation in combination with pembrolizumab plus carboplatin / pemetrexed will be restricted to patients with non-small cell lung cancer (NSCLC). In the expansion stage of the study, additional patients with epithelial ovarian carcinoma (EOC), NSCLC, or small cell lung cancer (SCLC) / high-grade neuroendocrine tumors (HG-NET) will be treated at the MTD (or maximum tested dose if no MTD is identified, or dose below the MTD if there is evidence suggesting a more favorable risk / benefit profile). This stage will provide further characterization of the safety, efficacy, PK, and pharmacodynamics, including biomarkers of immunologic activity and LXR target activation, of RGX-104 as a single agent (EOC), in combination with docetaxel (SCLC / HG-NET), and and in combination with pembrolizumab plus carboplatin / pemetrexed (NSCLC).
    Location: 8 locations

  • Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms

    This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 10 locations

  • Azacitidine, Entinostat, and Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer

    This phase II trial studies how well azacitidine, entinostat, and nivolumab or nivolumab alone work in treating patients with non-small cell lung cancer that has come back and has spread to other places in the body. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may kill tumor cells that are left after chemotherapy. It is not yet known if azacitidine and entinostat followed by nivolumab or nivolumab alone is more effective in treating non-small cell lung cancer.
    Location: 8 locations

  • Radiation Therapy to Relieve Symptoms in Patients with Advanced Non-Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of cyclical hypofractionated palliative radiation therapy (Quad Shot) in relieving symptoms of patients with stage IV non-small cell lung cancer. Radiation therapy is frequently used to relieve symptoms in patients with non-small cell lung cancer that has spread to other places in the body (advanced or metastatic). The Quad Shot treatment schedule reduces the number of days needed to deliver the radiation treatments, which may be less disruptive to systemic therapy schedules. The purpose of this trial is to find out whether Quad Shot radiation treatments can relieve the symptoms of non-small cell lung cancer while causing few or mild side effects.
    Location: 7 locations

  • Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.
    Location: 8 locations

  • Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

    The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
    Location: 7 locations

  • Dacomitinib and Osimertinib in Treating Patients with Metastatic EGFR Mutant Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of dacomitinib and osimertinib in treating patients with EGFR mutant non-small cell lung cancer that has spread to other places in the body. Dacomitinib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Early Stereotactic Body Radiation Therapy or High-Dose Radiotherapy in Treating Patients with Metastatic Breast or Non-small Cell Lung Cancer

    This phase II trial studies how well early stereotactic body radiation therapy (SBRT) or high-dose radiotherapy works in treating patients with breast or non-small cell lung cancer that has spread to other places in the body (metastatic). SBRT or high-dose radiotherapy has been shown to shrink or stabilize breast and non-small cell lung cancer. It is not yet known whether starting SBRT or high-dose radiotherapy when metastatic tumors have just begun to grow will extend life, compared with the usual approach to managing breast or non-small cell lung cancer.
    Location: 7 locations

  • Osimertinib Plus Savolitinib in EGFRm+ / MET+ NSCLC Following Prior Osimertinib

    This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
    Location: 7 locations

  • Dacomitinib with or without Osimertinib in Treating Patients with Metastatic EGFR Mutant Lung Cancers with Disease Progression on Osimertinib

    This early phase I trial studies how well dacomitinib with or without osimertinib works in treating patients EGFR mutant lung cancers that has spread to other places in the body (metastatic) and has progressed after treatment with osimertinib. Dacomitinib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

    The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with advanced non-small cell lung cancer and metastatic triple-negative breast cancer.
    Location: 9 locations

  • A Study of a Personalized Neoantigen Cancer Vaccine

    The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.
    Location: 9 locations

  • Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

    This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cobimetinib may work better in treating patients with non-small cell lung cancer.
    Location: 8 locations

  • Osimertinib, Carboplatin, Cisplatin, and Etoposide in Treating Patients with Metastatic Non-small Cell Lung Cancer with EGFR, RB1, and P53 Mutations

    Mutations are changes in DNA, the genetic material that serves as the body’s instruction book. Some of genetic mutations result in uncontrolled cellular replication and subsequently tumor formation. This phase I trial studies the side effects of osimertinib, carboplatin, cisplatin, and etoposide in treating patients with EGFR, RB1, and P53 mutant non-small cell lung cancer that has spread to other places in the body. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, cisplatin, or etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving osimertinib, carboplatin, cisplatin, and etoposide may work better at treating non-small cell lung cancer.
    Location: 7 locations

  • Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1 / PD-L1 Containing Therapy

    This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1 / PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
    Location: 7 locations

  • A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

    This is a Phase 1a / 1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).
    Location: 12 locations

  • U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

    This study has two parts: dose escalation and dose expansion. The primary objectives are: - For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion of U3-1402 in the study population - For Dose Expansion, to investigate the antitumor activity of U3-1402 The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met.
    Location: 7 locations

  • Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation

    This phase I / II trial studies the side effects of trametinib when given together with erlotinib hydrochloride and to see how well they work in treating patients with lung cancer that has an EGFR activating mutation and is stage IV or has come back. Trametinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

    The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
    Location: 10 locations

  • Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

    The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
    Location: 9 locations

  • A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

    The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
    Location: 8 locations